AI Article Synopsis
- Head and neck osteosarcoma (HNOS) is a rare bone tumor with limited treatment guidance, and data was collected from the National Cancer Database (NCDB) for analysis.
- A total of 821 patients diagnosed with HNOS showed an increase in the use of neoadjuvant chemotherapy combined with surgery from 2004 to 2016, with a 5-year overall survival (OS) rate of 55.8% among those who underwent surgery.
- While the study found no significant overall survival benefit from perioperative chemotherapy or radiation, patients receiving both neoadjuvant and adjuvant chemotherapy experienced improved short-term survival, indicating the need for further research.
Article Abstract
Background: Head and neck osteosarcoma (HNOS) is a rare primary bone tumor with limited data to guide treatment approaches.
Methods: The NCDB was used to identify patients diagnosed with HNOS. Kaplan-Meier and Cox multivariate regression were used to examine the impact of each treatment on overall survival (OS).
Results: We identified 821 patients diagnosed with HNOS. Utilization of neoadjuvant chemotherapy + surgery increased from zero cases in 2004 to 24% of cases in 2016. Among surgically treated patients, 5-year OS was 55.8% (CI: 51.7-60.1%). No difference was seen in OS between each treatment cohort on multivariate analysis. However, neoadjuvant chemotherapy + surgery + adjuvant chemotherapy had improved 18-month survival compared to surgery alone (95.8% vs. 78.5%, p = 0.031).
Conclusions: Our study demonstrated no survival benefit in perioperative chemotherapy or radiation therapy; however, short-term survival improvement in patients receiving both neoadjuvant and adjuvant chemotherapy displays promise and requires further investigation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.26817 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!